利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

61 条记录 (耗时 0.024 秒)

    METHOD, EQUIPMENT AND SPECIFIC DRAWER FOR MEMBRANE SEPARATION UTILIZING CONCENTRATION POLARIZATION
    52.
    发明申请
    METHOD, EQUIPMENT AND SPECIFIC DRAWER FOR MEMBRANE SEPARATION UTILIZING CONCENTRATION POLARIZATION 有权
    方法，设备和特殊抽屉用于膜分离利用浓度极化

    公开(公告)号：US20120285889A1

    公开(公告)日：2012-11-15

    申请号：US13555668

    申请日：2012-07-23

    申请人： Yinhua Wan ,  Xiangrong Chen ,  Zhiguo Su ,  Guanghui Ma ,  Xiaoguang Jiao ,  Fei Shen ,  Zhanfeng Cui

    发明人： Yinhua Wan ,  Xiangrong Chen ,  Zhiguo Su ,  Guanghui Ma ,  Xiaoguang Jiao ,  Fei Shen ,  Zhanfeng Cui

    IPC分类号： B01D61/14 ,  B01D61/36

    CPC分类号： B01D65/08 ,  B01D61/145 ,  B01D61/147 ,  B01D63/082 ,  B01D2321/26

    摘要： The present invention relates to a membrane separation method and a relevant equipment, in particular to a method and an equipment for membrane separation utilizing concentration polarization during membrane filtration process, especially, to a concentration process and equipment and a drawer special for drawing a concentration polarization layer. The direct removal of the concentration polarization layer from membrane surface not only decreases the adverse influence of concentration polarization on membrane separation but also obtains concentrated retention components, thereby significantly improving the ability to maintain membrane flux, solving the twinborn problems concerning concentration polarization and membrane fouling during the membrane separation process, and achieving a high-efficiency concentration for retention components. The method and equipment of the present invention can be widely applied in various membrane techniques, in particular in a membrane separation process for concentrating biomacromolecule and organic micromolecule products such as sugars, organic acids and polypeptides etc.

    摘要翻译： 本发明涉及一种膜分离方法和相关设备，特别涉及在膜过滤过程中利用浓度极化的膜分离方法和设备，特别涉及浓缩过程和设备以及特别用于绘制浓缩极化的抽屉 层。 从膜表面直接除去浓缩极化层不仅降低了浓度极化对膜分离的不利影响，而且获得了浓缩的保留成分，从而显着提高了保持膜通量的能力，解决了浓度极化和膜污染的双胎问题 在膜分离过程中，并且实现保留成分的高效浓缩。 本发明的方法和设备可以广泛地应用于各种膜技术中，特别是在用于浓缩生物大分子和有机小分子产物如糖，有机酸和多肽等的膜分离方法中。

    METHOD, EQUIPMENT AND SPECIFIC DRAWER FOR MEMBRANE SEPARATION UTILIZING CONCENTRATION POLARIZATION
    54.
    发明申请
    METHOD, EQUIPMENT AND SPECIFIC DRAWER FOR MEMBRANE SEPARATION UTILIZING CONCENTRATION POLARIZATION 有权
    方法，设备和特殊抽屉用于膜分离利用浓度极化

    公开(公告)号：US20100044310A1

    公开(公告)日：2010-02-25

    申请号：US12443797

    申请日：2008-03-05

    申请人： Yinhua Wan ,  Xiangrong Chen ,  Zhiguo Su ,  Guanghui Ma ,  Xiaoguang Jiao ,  Fei Shen ,  Zhanfeng Cui

    发明人： Yinhua Wan ,  Xiangrong Chen ,  Zhiguo Su ,  Guanghui Ma ,  Xiaoguang Jiao ,  Fei Shen ,  Zhanfeng Cui

    IPC分类号： B01D65/08 ,  B01D63/00 ,  B01D65/00

    CPC分类号： B01D65/08 ,  B01D61/145 ,  B01D61/147 ,  B01D63/082 ,  B01D2321/26

    摘要： The present invention relates to a membrane separation method and a relevant equipment, in particular to a method and an equipment for membrane separation utilizing concentration polarization during membrane filtration process, especially, to a concentration process and equipment and a drawer special for drawing a concentration polarization layer. The direct removal of the concentration polarization layer from membrane surface not only decreases the adverse influence of concentration polarization on membrane separation but also obtains concentrated retention components, thereby significantly improving the ability to maintain membrane flux, solving the twinborn problems concerning concentration polarization and membrane fouling during the membrane separation process, and achieving a high-efficiency concentration for retention components. The method and equipment of the present invention can be widely applied in various membrane techniques, in particular in a membrane separation process for concentrating biomacromolecule and organic micromolecule products such as sugars, organic acids and polypeptides etc.

    摘要翻译： 本发明涉及一种膜分离方法和相关设备，特别涉及在膜过滤过程中利用浓度极化的膜分离方法和设备，特别涉及浓缩过程和设备以及特别用于绘制浓缩极化的抽屉 层。 从膜表面直接除去浓缩极化层不仅降低了浓度极化对膜分离的不利影响，而且获得了浓缩的保留成分，从而显着提高了保持膜通量的能力，解决了浓度极化和膜污染的双胎问题 在膜分离过程中，并且实现保留成分的高效浓缩。 本发明的方法和设备可以广泛地应用于各种膜技术中，特别是在用于浓缩生物大分子和有机小分子产物如糖，有机酸和多肽等的膜分离方法中。

    Gel antiperspirant composition containing volatile linear silicone and calcium enhanced antiperspirant salt
    55.
    发明授权
    Gel antiperspirant composition containing volatile linear silicone and calcium enhanced antiperspirant salt 有权
    凝胶止汗组合物含挥发性线性硅胶和钙增强止汗剂盐

    公开(公告)号：US06911195B2

    公开(公告)日：2005-06-28

    申请号：US10320202

    申请日：2002-12-16

    申请人： Tuan M. Vu ,  Yan-Fei Shen

    发明人： Tuan M. Vu ,  Yan-Fei Shen

    IPC分类号： A61K8/06 ,  A61K8/28 ,  A61K8/58 ,  A61K8/894 ,  A61K8/898 ,  A61Q15/00 ,  A61K7/32 ,  A61K7/34 ,  A61K7/38 ,  A61K7/00

    CPC分类号： A61K8/894 ,  A61K8/0216 ,  A61K8/042 ,  A61K8/06 ,  A61K8/064 ,  A61K8/28 ,  A61K8/585 ,  A61K2800/262 ,  A61K2800/882 ,  A61Q5/065 ,  A61Q5/10 ,  A61Q15/00

    摘要： Disclosed are antiperspirant compositions, particularly clear gel antiperspirant compositions, that are water-in-silicone oil emulsions. The emulsion includes a water phase, typically comprising about 65% to about 95% by weight of the emulsion, and a silicone oil phase, typically comprising about 5% to about 35% by weight of the emulsion. The water phase includes an antiperspirant salt dissolved therein, typically in an amount of about 8% to about 30% by weight of the emulsion, the antiperspirant salt comprising a calcium enhanced aluminum-zirconium chlorohydrate. The silicone oil phase contains less than about 5% by weight of the emulsion of a non-volatile oil and includes about 2% to about 25% by weight of the emulsion of a volatile linear silicone.

    摘要翻译： 公开了防水剂组合物，特别是透明的凝胶止汗组合物，其是水包硅油乳液。 乳液包括水相，通常占乳液重量的约65％至约95％，硅油相通常占乳液重量的约5％至约35％。 水相包括其中溶解的止汗盐，通常为乳液重量的约8％至约30％，止汗剂盐包含钙增强的铝 - 锆氯化水合物。 硅油相包含小于非挥发性油的乳液的约5重量％，并且包含挥发性线性硅氧烷的乳液的约2重量％至约25重量％。

    Aluminum-zirconium antiperspirant salts with high peak 5 Al content
    56.
    发明授权
    Aluminum-zirconium antiperspirant salts with high peak 5 Al content 有权
    具有高峰5 Al含量的铝锆止汗盐

    公开(公告)号：US06649152B2

    公开(公告)日：2003-11-18

    申请号：US10138476

    申请日：2002-05-03

    申请人： Angel L. Carrillo ,  Richard Oryszczak ,  Yan-Fei Shen

    发明人： Angel L. Carrillo ,  Richard Oryszczak ,  Yan-Fei Shen

    IPC分类号： A61K732

    CPC分类号： A61Q15/00 ,  A61K8/28 ,  C01G25/006 ,  C01P2002/87 ,  Y10S424/05

    摘要： Disclosed are enhanced efficacy aluminum-zirconium antiperspirant salt compositions which exhibit an HPLC peak 5 area content of about 33% or more, preferably at least 45%, more preferably at least 50%, most preferably at least 55%. Especially preferred are aluminum-zirconium antiperspirant salt compositions which, in addition to the aforementioned high peak 5 content, also exhibit an HPLC peak 4 to peak 3 area ratio of at least 0.4, preferably at least 0.7. The aforementioned salt compositions will preferably have a metal (Al+Zr) to chloride (or anion) ratio of about 0.90 to about 1.00. Also disclosed are methods of making such antiperspirant salt compositions and aqueous solutions of such antiperspirant salt compositions. Further disclosed are topical compositions comprising a dermatologically acceptable carrier vehicle and a perspiration reducing effective amount of an aluminum-zirconium antiperspirant salt composition as described above.

    摘要翻译： 公开了增强的效力铝锆止汗剂盐组合物，其显示出HPLC峰值5面积含量为约33％或更高，优选至少45％，更优选至少50％，最优选至少55％。 特别优选的是铝 - 锆止汗剂盐组合物，除了上述高峰5含量之外，还显示HPLC峰4至峰3面积比至少为0.4，优选至少0.7。 上述盐组合物优选具有约0.90至约1.00的金属（Al + Zr）与氯化物（或阴离子）的比例。 还公开了制备这种止汗剂盐组合物和这种止汗剂盐组合物的水溶液的方法。 进一步公开的是包含皮肤病学可接受的载体载体和减少有效量的如上所述的铝 - 锆止汗剂盐组合物的汗液的局部组合物。

    Aluminum-zirconium antiperspirant salts with high peak 5 al content
    57.
    发明授权
    Aluminum-zirconium antiperspirant salts with high peak 5 al content 有权
    具有高峰5 al含量的铝 - 锆止汗盐

    公开(公告)号：US06436381B1

    公开(公告)日：2002-08-20

    申请号：US09696271

    申请日：2000-10-25

    申请人： Angel L. Carrillo ,  Richard Oryszczak ,  Yan-Fei Shen

    发明人： Angel L. Carrillo ,  Richard Oryszczak ,  Yan-Fei Shen

    IPC分类号： A61K732

    CPC分类号： A61Q15/00 ,  A61K8/28 ,  C01G25/006 ,  C01P2002/87 ,  Y10S424/05

    摘要： Disclosed are enhanced efficacy aluminum-zirconium antiperspirant salt compositions which exhibit an HPLC peak 5 area content of about 33% or more. Especially preferred are aluminum-zirconium antiperspirant salt compositions which, in addition to the aforementioned high peak 5 content, also exhibit an HPLC peak 4 to peak 3 area ratio of at least 0.4. The aforementioned salt compositions will preferably have a metal (Al+Zr) to chloride (or anion) ratio of about 0.90 to about 1.00. Also disclosed are methods of making such antiperspirant salt compositions and aqueous solutions of such antiperspirant salt compositions. Further disclosed are topical compositions comprising a dermatologically acceptable carrier vehicle and a perspiration reducing effective amount of an aluminum-zirconium antiperspirant salt composition as described above.

    摘要翻译： 公开了增强的效能铝锆防汗剂盐组合物，其显示出HPLC峰值5面积含量为约33％或更高。 特别优选的是铝 - 锆止汗剂盐组合物，除了上述高峰5含量之外，还显示HPLC峰4至峰3面积比至少为0.4。 上述盐组合物优选具有约0.90至约1.00的金属（Al + Zr）与氯化物（或阴离子）的比例。 还公开了制备这种止汗剂盐组合物和这种止汗剂盐组合物的水溶液的方法。 进一步公开的是包含皮肤病学可接受的载体载体和减少有效量的如上所述的铝 - 锆止汗剂盐组合物的汗液的局部组合物。

    Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
    58.
    发明授权
    Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists 失效
    使用低剂量的阿片受体拮抗剂治疗肠易激综合征的方法和组合物

    公开(公告)号：US06395705B2

    公开(公告)日：2002-05-28

    申请号：US09754840

    申请日：2001-01-04

    申请人： Stanley M. Crain ,  Ke-fei Shen ,  Gerald M. Fleischner

    发明人： Stanley M. Crain ,  Ke-fei Shen ,  Gerald M. Fleischner

    IPC分类号： A61K3800

    CPC分类号： A61K31/485 ,  A61K31/00

    摘要： This invention relates to a method for treating a subject with irritable bowel syndrome (“IBS”) which comprises long-term administration of an opioid receptor antagonist at an appropriately low dose which will selectively antagonize excitatory opioid receptor functions, but not inhibitory opioid receptor functions, in myenteric neurons in the intestinal tract as well as in neurons of the central nervous system (“CNS”). The administration of the opioid receptor antagonist at a low dose enhances the potency of the inhibitory effects of endogenous opioid peptides present in the intestinal tract and the CNS, thereby reducing abdominal pain and stool frequency resulting from abnormally supersensitized excitatory opioid receptor functions. The invention also relates to a composition for treating a subject with IBS, which comprises an effective dose of an opioid receptor antagonist, and a pharmaceutically acceptable carrier.

    摘要翻译： 本发明涉及用于治疗肠易激综合征（“IBS”）的受试者的方法，其包括以适当低剂量长期施用阿片受体拮抗剂，其将选择性拮抗兴奋性阿片受体功能，但不抑制阿片受体功能 ，在肠道的肠系膜神经元以及中枢神经系统的神经元（“CNS”）中。 以低剂量施用阿片样物质受体拮抗剂增强了存在于肠道和CNS中的内源性阿片样物质肽的抑制作用的效力，从而降低了由异常超敏刺激性阿片受体功能引起的腹痛和大便频率。 本发明还涉及用IBS治疗受试者的组合物，其包含有效剂量的阿片受体拮抗剂和药学上可接受的载体。

    Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
    60.
    发明授权
    Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists 失效
    使用低剂量的阿片受体拮抗剂治疗肠易激综合征的方法和组合物

    公开(公告)号：US06194382B1

    公开(公告)日：2001-02-27

    申请号：US09261361

    申请日：1999-03-03

    申请人： Stanley M. Crain ,  Ke-fei Shen ,  Gerald M. Fleischner

    发明人： Stanley M. Crain ,  Ke-fei Shen ,  Gerald M. Fleischner

    IPC分类号： A61K3800

    CPC分类号： A61K31/485 ,  A61K31/00

    摘要： This invention relates to a method for eating a subject with irritable bowel syndrome (“IBS”) which comprises long-term administration of an opioid receptor antagonist at an appropriately low dose which will selectively antagonize excitatory opioid receptor functions, but not inhibitory opioid receptor functions, in myenteric neurons in the intestinal tract as well as in neurons of the central nervous system (“CNS”). The administration of the opioid receptor antagonist at a low dose enhances the potency of the inhibitory effects of endogenous opioid peptides present in the intestinal tract and the CNS, thereby reducing abdominal pain and stool frequency resulting from abnormally supersensitized excitatory opioid receptor functions. The invention also relates to a composition for treating a subject with IBS, which comprises an effective dose of an opioid receptor antagonist, and a pharmaceutically acceptable carrier.

    摘要翻译： 本发明涉及一种吃肠易激综合征（“IBS”）的方法，其包括以适当低剂量长期施用阿片样物质受体拮抗剂，其将选择性拮抗兴奋性阿片受体功能，但不抑制阿片受体功能 ，在肠道的肠系膜神经元以及中枢神经系统的神经元（“CNS”）中。 以低剂量施用阿片样物质受体拮抗剂增强了存在于肠道和CNS中的内源性阿片样物质肽的抑制作用的效力，从而降低了由异常超敏刺激性阿片受体功能引起的腹痛和大便频率。 本发明还涉及用IBS治疗受试者的组合物，其包含有效剂量的阿片受体拮抗剂和药学上可接受的载体。